BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced on Monday that it has named Emile Nuwaysir, PhD as its new board chair, effective 1 August 2021.
Presently, Nuwaysir is the BlueRock Therapeutics president and CEO. He joined the company in 2020. The company said that he has experience building a small biotech and deep understanding of how to work and thrive within a large pharmaceutical ecosystem. He has brought various cellular therapies from invention to clinical testing.
In the new role, Dr Nuwaysir will continue to take an active role in the growth and maturation of the company, offering guidance and support on both corporate strategy and R&D.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer